L6545
来曲唑
≥98% (HPLC), powder, non-steroidal aromatase inhibitor
别名:
4,4′-(1H-1,2,4-三唑-1-基亚甲基）双苄腈
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C17H11N5
化学文摘社编号:
分子量:
285.30
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
来曲唑, ≥98% (HPLC)
SMILES string
N#CC(C=C1)=CC=C1C(N2C=NC=N2)C3=CC=C(C#N)C=C3
InChI key
HPJKCIUCZWXJDR-UHFFFAOYSA-N
InChI
1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H
assay
≥98% (HPLC)
form
powder
color
white to off-white
solubility
DMSO: >50 mg/mL
originator
Novartis
storage temp.
2-8°C
Quality Level
Gene Information
human ... CYP19A1(1588)
正在寻找类似产品? 访问 产品对比指南
Application
来曲唑已用于：
- 在类器官生长试验中测定其抑制力（48）
- 研究类固醇受体共激活因子1（SRC-1）介导的海马PSD-95内源性雌激素调节作用（49）
- 研究其对肿瘤诱导的痛觉过敏的作用 （50）
- 对大鼠进行激素干预（51）研究其对脂质运载蛋白-2（Lcn2）的作用（52）研究其对机械痛觉过敏和芳香化酶表达的作用（53）
Biochem/physiol Actions
来曲唑是一种佐剂，可用于治疗乳腺癌。
来曲唑是一种非甾体芳香酶抑制剂。
来曲唑是第三代非甾体芳香酶抑制剂。 它是芳香酶系统的竞争性抑制剂，因此可抑制雄激素向雌激素转化。来曲唑通过竞争性结合到该酶的细胞色素P450亚基的血红素上而抑制芳香酶，导致所有组织中雌激素的生物合成减少。
signalword
Warning
hcodes
Hazard Classifications
Repr. 2 - STOT RE 2
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Bianca Posocco et al.
PloS one, 15(2), e0228822-e0228822 (2020-02-08)
A novel LC-MS/MS method was developed for the quantification of the new cyclin dependent kinase inhibitors (CDKIs) palbociclib and ribociclib and the aromatase inhibitor letrozole used in combinatory regimen. The proposed method is appropriate to be applied in clinical practice
Natalia Lagunas et al.
Frontiers in neuroanatomy, 16, 902218-902218 (2022-07-12)
Sex steroid hormones, such as androgens and estrogens, are known to exert organizational action at perinatal periods and activational effects during adulthood on the brain and peripheral tissues. These organizational effects are essential for the establishment of biological axes responsible
Zahra Shaaban et al.
Iranian journal of basic medical sciences, 25(1), 110-120 (2022-06-04)
Despite prevalence of polycystic ovary syndrome (PCOS) among childbearing women and development of many animal models for this syndrome, information on its etiology is still scarce. The intrauterine hyperandrogenic environment may underlie changes at the level of hypothalamus, pituitary, ovary
Drugs for Pregnant and Lactating Women E-Book (2009)
Pamela J Goodwin et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(21), 2231-2239 (2014-06-18)
Obesity is associated with poor outcomes in women with operable breast cancer. Lifestyle interventions (LIs) that help women reduce their weight may improve outcomes. We conducted a multicenter randomized trial comparing mail-based delivery of general health information alone or combined
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持